ezPaycheck 2026-2027 Bundle Integrates Direct IRS E-Filing to Help SMBs and Accountants Prevent Costly Tax Penalties

REDMOND, Wash., Oct. 21, 2026 /PRNewswire/ -- Halfpricesoft.com is highlighting its streamlined Form 941 e-file add-on feature for ezPaycheck payroll software ahead of the upcoming Q3 tax deadline. With the official deadline to submit IRS Form 941 for 2026 Q3 (July–September) fast approaching on Monday, November 2, 2026 (as October 31 falls on a Saturday), small businesses can leverage ezPaycheck to submit payroll taxes accurately and directly to the IRS, avoiding processing delays and costly late penalties.

Ensure the Q3 payroll taxes are compliant before November 2. Download a complimentary 30-day trial of ezPaycheck (no credit card required) or purchase the 2026-2027 ezPaycheck bundle for $378 (regularly $289).

Key Benefits of E-Filing Form 941 via ezPaycheck

- Faster Direct Transmission: E-filed forms transmit straight to the IRS, ensuring faster receipt and processing compared to traditional mail.

- On-Time Compliance: Businesses can e-file right up to the November 2 deadline while maintaining full IRS compliance, backed by Halfpricesoft.com support before, during, and after setup.

- Fewer Errors & Rejections: Built-in verification reduces common manual input errors that trigger processing delays or fines.

- Instant Confirmation: Users receive explicit IRS confirmation upon successful form receipt.

"With the e941 feature add-on in ezPaycheck, businesses have a tool to succeed, one form at a time." said Dr. Ge, Founder of Halfpricesoft.com

Get Form 941 E-Filing Details & Instructions

Frequently Asked Questions

- What happens if the filing deadline is missed?

Late filings can result in IRS penalties ranging from $50 to $290 per form, depending on how long the submission is delayed.

- Can both Form 940 and Form 941 be e-filed through ezPaycheck?

ezPaycheck supports e-filing for both Form 940 (Employer's Annual Federal Unemployment Tax Return) and Form 941 (Employer's Quarterly Federal Tax Return) to maintain full compliance.

Easily calculate taxes, issue paychecks for employees and contractors, and generate all required reports and tax forms, including W-2, W-3, 940, 941, and 943. Because ezPaycheck runs locally, no internet connection is required to process payroll, keeping your data private and secure

All Halfpricesoft.com solutions are updated annually to ensure full alignment with current state and federal tax regulations. Multi-user configurations and advanced operational features are available across the product line. Start today to explore software solutions and download a trial version.

About Halfpricesoft.com

Halfpricesoft.com has been empowering SMBs, Accountants, and Entrepreneurs to simplify payroll and compliance for more than 20 years. Trusted by thousands of U.S. companies, the firm offers affordable, easy-to-use solutions including online and desktop payroll, employee attendance tracking, accounting, check printing, W-2/1099/1095 ACA form filing, and ezACH direct deposit software. 

SOURCE Halfpricesoft.com

Share this article

Valmet's key technology delivery supports efficient and flexible pulp production at the new Century Sunshine Rizhao mill in China

Valmet Oyj's press release on October 21, 2026 at 09:30 a.m. EEST

ESPOO, Finland, Oct. 21, 2026 /PRNewswire/ -- Valmet is delivering key technology for Century Sunshine's new Rizhao pulp mill that is being built in Shandong province in China. Valmet's delivery includes cooking and fiberlines, an evaporation plant, a recovery boiler with optimizers, ash treatment and a white liquor plant.

The new pulp mill is part of Century Sunshine's strategic three-phase investment program 'Paper-for-Plastic', which aims for 2.65 million tonnes of annual new paper production with the goal of plastics replacement with various paper-based products. The new pulp mill is designed to have an annual capacity of 1.2 million tonnes of hardwood or softwood pulp and 400,000 tonnes of softwood pulp.

The order was included in Valmet's orders received for the second quarter of 2026. The value of the order exceeds EUR 100 million. The exact value of the order will not be disclosed. The new mill is expected to start up in June 2028.

"This project is at the core of our strategy to improve our self-sufficiency in raw material supply and meet the evolving needs of customers in the Chinese market. We chose Valmet as a partner for this project based on our positive previous experiences and their ability to meet our project needs both regarding technology and our investment budget," says Jeff Cheng, Vice President, Century Sunshine.

"Valmet has a long-term partnership with Century Sunshine with our paper technology, and we will now strengthen our cooperation with this pulp mill delivery. This delivery showcases not only customer trust in Valmet but also highlights our competitiveness in China. For example, we have increased the share of locally manufactured parts for the evaporation plant. With our strong local technology and service organization in China we will be able to support the customer throughout the mill's lifecycle," says Xiangdong Zhu, Executive Vice President, China Chair, Valmet.

"The new Century Sunshine Rizhao mill will produce fluff, dissolving, softwood and hardwood pulp, and is an excellent example of product differentiation to meet the growing market needs with Valmet's full scope offering. The mill features the latest cooking technology, a high-power recovery boiler with leading optimization and safety features, and electrostatic precipitator for efficient dust emissions reduction," says Andreas Michalik, Vice President, Pulp Mills, Pulp, Energy and Circularity Business Area, Valmet.

Energy efficiency and long-term availability in technology focus

Valmet's delivery for the new Century Sunshine Rizhao mill includes complete cooking and fiberlines, and the recovery island. There will be two parallel cooking and fiberlines, one of which is a Valmet Continuous Cooking swing line producing bleached softwood or hardwood pulp, and another line producing bleached softwood pulp aimed for fluff and dissolving pulp production. The lines feature Valmet TwinRoll Press -based washing and screening as well as White Liquor Oxidation.

The recovery island consists of an Evaporation plant with Valmet Tubel technology, a high-power Recovery Boiler, an Ash Crystallization plant, a Recausticizing plant and two Lime Kilns with integrated Biomass Dryers and Gasifiers. Safe and efficient operations of the recovery boiler are secured with Valmet Electrostatic Precipitators (ESP), Valmet Smelt Spout Robot, Optimizers and Furnace Camera. The lime kilns are equipped with Valmet ESP and are designed to use biomass as fuel, making the mill fossil-fuel free.

About the customer Century Sunshine Paper Group

Century Sunshine (Rizhao) Pulp and Paper is part of the Century Sunshine Paper Group, a pulp and paper manufacturer headquartered in Weifang, Shandong Province, China. Founded in 2000 and listed on the Hong Kong Stock Exchange, the company focuses on the production of high-grade packaging papers, including white top linerboard, coated kraft paper, corrugated medium, and specialty papers. With multiple subsidiaries and large-scale production facilities, Century Sunshine operates an integrated value chain spanning pulp, paper manufacturing, and packaging solutions.

VALMET

Corporate Communications

Further information:

Sanna Röyskö, Vice President, Pulp Mill Sales, Pulp, Energy and Circularity Business Area, Valmet, tel. +358 40 821 1268

Xiangdong Zhu, Executive Vice President, China Chair, Valmet, tel. +86 138 017 957 75

Valmet is a global technology leader in serving process industries. We work with our customers throughout the lifecycle, delivering cutting-edge technologies and services, as well as mission-critical automation and flow control solutions. Backed by more than 225 years of industrial experience and a global team of 18,500 professionals close to customers, we are uniquely positioned to transform industries toward a regenerative tomorrow.

In 2025, Valmet's net sales totaled approximately EUR 5.2 billion. Our head office is in Espoo, Finland, and we have experts in approximately 40 countries around the world. Valmet's shares are listed on Nasdaq Helsinki.

Follow us on valmet.com | X | LinkedIn | Facebook | YouTube | Instagram | Instagram (IR)

This information was brought to you by Cision http://news.cision.com

Share this article

VANCOUVER, BC, Oct. 21, 2026 /PRNewswire/ -- Nevada Organic Phosphate Inc. ("NOP" or the "Company") (CSE: NOP) (OTCQB: NOPFF) (FSE: ZV8), a B.C. based leader in organic sedimentary phosphate exploration, is pleased to report that Hole MM26-12 intersected a strong 37.4 metres (94.2 feet) of the target Meade Peak Member. Oolitic zones typical of the Upper Phosphate Zone were noted during core logging. True thickness and the phosphate content of the Upper Phosphatic Zone will be confirmed by assay.

MM26-12 is approximately 200 metres (656 feet) further along trend to the southwest from MM26‑11, which brings the confirmed strike of the target zone to over 3.5 kilometres (2.2 miles).

Robin Dow, CEO, commented: "We are very excited to be able to increase our drilling production with MM26‑12, also intersecting the Meade Peak with visual indications of the Upper Phosphate Zone. This extends our confirmed strike length of phosphate mineralization to over 3.5 kilometres, marking continued and meaningful progress de‑risking our geological model."

Garry Smith, P.Geo., Director, added: "our drilling production has improved steadily and MM26-12 was completed without significant complications. This Meade Peak intersection in this hole was a strong 37.4 metres with lots of oolites. Although we must wait for assays, we are very excited by these observations in our western-most hole that we have drilled."

Drill Collars and Proposed Drill Pad Locations

(all values are UTM NAD83, and in metres, "decimals" denote surveyed)

Qualified Person

The interpretive technical information in this news release has been reviewed and approved by Garry K Smith, P.Geo., a Director and Qualified Person, as defined in "National Instrument 43-101, Standards of Disclosure for Mineral Projects.

Nevada Organic Phosphate Inc. (CSE: NOP) (OTCQB: NOPFF) (FSE: ZV8)

NOP is a junior exploration company with an organic certifiable sedimentary raw rock phosphate bed, 6.6 kilometres long, in northeast Nevada. Additional applications extend the potential strike of rock phosphate to over 30 kilometres. This is believed to be the only known large-scale organic certifiable sedimentary phosphate project in North America. It is situated close to the main highway to Montello/Elko, Nevada, and the rail head to California or the East Coast.

Neither the Canadian Securities Exchange nor its regulations services providers have reviewed or accept responsibility for the adequacy or accuracy of this release.

This news release may contain forward-looking statements and information ("FLSI") within the meaning of applicable securities laws. FLSI may include expectations, anticipations, beliefs, opinions, plans, intentions, estimates, forecasts, projections, guidance or other similar statements and information that are not historical facts. All statements which are not historical statements are considered FLSI. All FLSI is based on assumptions, which may prove inaccurate, and subject to certain risks and uncertainties, including without limitation those risks and uncertainties identified in the Company's public securities filings, which may cause actual events or results to differ materially from those indicated or implied in FLSI. Accordingly, readers should not place undue reliance or value on FLSI. Although the Company believes that the expectations reflected in any FLSI in this news release are reasonable at the present time, it can give no assurance that such FLSI will prove to be correct. Any FLSI in this news release is made as of the date hereof and the Company undertakes no obligations to publicly update or revise any FLSI, whether as a result of new information, future events or otherwise, unless required by applicable securities laws. Any FLSI in this news release is expressly qualified in its entirety by this cautionary statement

SOURCE Nevada Organic Phosphate Inc.

Share this article

- Recorded Q3'26 revenue of KRW 1,490 billion and operating profit of KRW 640 billion

- Plant 5 ramp-up and U.S. manufacturing operations contribute to earnings performance

- Raised 2026 revenue growth guidance to 20% while advancing strategic investments in portfolio and capacity expansion

INCHEON, South Korea, Oct. 21, 2026 /PRNewswire/ -- Samsung Biologics (KRX: 207940.KS), a leading contract development and manufacturing organization (CDMO), reported financial results for the third quarter of fiscal year 2026.

"As global pharmaceutical pipelines become more diverse and supply requirements increasingly complex, the ability to execute consistently across manufacturing programs is ever more important," said John Rim, President and CEO of Samsung Biologics. "We are strategically expanding our manufacturing capacity, multi-modality capabilities, and global operations to address these evolving needs. Our priority is to translate these investments into sustainable growth through disciplined execution and a continued focus on delivering value to our clients."

Financial Highlights

Samsung Biologics reported third-quarter revenue of KRW 1,490 billion and operating profit of KRW 640 billion, supported by Plants 1 through 4 operating at full capacity and increasing contributions from Plant 5 as production ramps up. The company's Rockville manufacturing facility in Maryland, U.S., also contributed to revenue during the quarter, marking its initial contribution to the revenue following the acquisition.

Samsung Biologics continued to demonstrate strong commercial momentum, with cumulative contract orders exceeding USD 21.9 billion, reflecting sustained demand for its development and manufacturing services.

Business Updates and 2026 Outlook

Samsung Biologics updated its 2026 annual revenue growth guidance to 20%, up from its previous range of 15–20%, reflecting confidence in its operational performance and growth trajectory.

The company reinforced operational efficiency and coordinated resource management across its manufacturing operations, with a focus on consistent project execution and manufacturing continuity. Its ExellenS™ framework, built on standardized facility designs, processes, and digital technologies, supports operational consistency and manufacturing readiness across its network.

Samsung Biologics maintained stable manufacturing operations and workforce capabilities at its Rockville site while evaluating opportunities to optimize the facility for a broader range of client requirements. Together with operations at Songdo, the facility expands Samsung Biologics' geographic manufacturing presence and strengthens the company's ability to accommodate U.S. and global demand.

Samsung Biologics also expanded its global commercial presence with the opening of a sales office in the Netherlands, strengthening local engagement with European pharmaceutical and biotechnology companies.

In October, the company published the interim results of the PolyPeptide Group public tender offer, successfully meeting the acceptance offer condition with 87.92% participation rate. The planned acquisition will expand Samsung Biologics' service portfolio into peptide-based therapeutics, complementing its existing capabilities in antibodies and conjugates. PolyPeptide's specialized development and manufacturing expertise, together with its operations across Europe, the U.S., and India, is expected to further diversify Samsung Biologics' global CDMO services in a growing segment of the market.

To support its next phase of growth, Samsung Biologics announced a KRW 3 trillion rights offering to fund strategic investments, including the planned PolyPeptide acquisition and future manufacturing capacity expansion. The offering is scheduled to proceed with existing shareholder subscriptions in November, followed by a general public offering of any unsubscribed shares.

On the sustainability front, Samsung Biologics received an 'A' rating in the latest Morgan Stanley Capital International (MSCI) ESG Ratings assessment demonstrating continued progress. The company also established a greenhouse gas emissions calculation system to improve emissions data management and strengthen its readiness for upcoming mandatory ESG disclosure requirements.

Looking ahead, Samsung Biologics remains focused on operational performance and disciplined implementation of strategic investments, while strengthening its capabilities to support clients across an expanding range of modalities and geographic markets.

For more details on performance and financials, please refer to the Earnings Release.

About Samsung Biologics Co., Ltd.

Samsung Biologics Co., Ltd., Incheon, Republic of Korea (KRX: 207940.KS) is a leading contract development and manufacturing organization (CDMO), offering end-to-end integrated services that range from late discovery to commercial manufacturing.

With a combined biomanufacturing capacity of 785,000 liters across Bio Campus I and II in Korea, and 60,000 from the manufacturing facility in Rockville, Maryland, U.S., Samsung Biologics holds total global manufacturing capacity of 845,000 liters. Samsung Biologics has also secured land for Bio Campus III, laying the groundwork for future capacity expansion to support next-generation therapies and emerging modalities.

Samsung Biologics leverages cutting-edge technologies and expertise to advance diverse modalities, including multispecific antibodies, fusion proteins, antibody-drug conjugates, and mRNA therapeutics.

By implementing the ExellenS™ framework across its manufacturing network with standardized designs, unified processes, and advanced digitalization, Samsung Biologics ensures plant equivalency and speed for manufacturing continuity.

Samsung Biologics' global manufacturing and commercial network spans Korea, the U.S., Europe, and Japan. Samsung Biologics continues to invest in new capabilities to maximize operational and quality excellence, ensuring flexibility and agility for clients. Samsung Biologics is committed to the on-time, in-full delivery of safe, high-quality biomedicines, as well as to making sustainable business decisions for the betterment of society and global health. For more information, please visit https://samsungbiologics.com.

Media contacts

Claire Kim, Senior Director [email protected]

Becky Lee, Director [email protected]

SOURCE Samsung Biologics

Share this article

Provident Place Demonstrates Integral Concrete Waterproofing for Marine Environments

As coastal projects face rising groundwater salinity and saltwater intrusion, Provident Place in Pompano Beach, Florida offers a practical example of how integral crystalline waterproofing can help protect below-grade concrete structures in marine environments. In June 2026, The Penetron System was specified for the affordable senior housing community's foundation slab, retaining walls, and elevator pits.

ORLANDO, Fla., Oct. 21, 2026 /PRNewswire/ -- Designed by Anillo, Toledo, Lopez, a Miami-based architectural office, Provident Place is an affordable senior housing community for residents aged 62 and older. The development comprises two mid-rise buildings with 100 elevator-accessible rental apartments in one- and two-bedroom layouts, supported by amenities including a community room, fitness center, dog park, and covered pavilion with grills for outdoor gatherings.

For architects and builders working in coastal and marine-adjacent locations, the project highlights a growing design consideration: protecting below-grade concrete from water ingress, chloride exposure, and corrosion risk linked to saline groundwater.

"Increasing saltwater intrusion in Broward County, where Pompano Beach is located, and the resultant increase in the salinity of the community's groundwater can quickly lead to corrosion of below-grade concrete structures," notes Dale Williams, General Sales Manager for Penetron USA.

To address these durability requirements, Supermix, the ready-mix concrete supplier, provided a concrete waterproofing solution for the below-grade foundation slab, retaining walls, and elevator pits. PENETRON ADMIX SB, a crystalline waterproofing admixture, and PENEBAR, a swellable waterstop for concrete joints, were specified as part of the concrete protection strategy.

Once added to the mix, the active ingredients in PENETRON ADMIX react to form a non-soluble crystalline structure throughout the pores and capillary tracts of the concrete. This permanently seals microcracks, pores, and capillaries against water or liquid penetration from any direction, helping provide long-term durability in aggressive marine environmental conditions.

"Provident Place is just the first stage in an ambitious revitalization of the Golden Acres neighborhood in Pompano Beach," adds Williams. "There are already plans to add a further four hundred units, which will offer more opportunities to prove the value of integral concrete waterproofing technology."

The PENETRON Group is a leading manufacturer of specialty construction products for concrete waterproofing, concrete repairs and floor preparation systems. The Group operates through a global network, offering support to the design and construction community through its regional offices, representatives and distribution channels.

For more information on PENETRON waterproofing solutions, please visit penetron(dot)com or Facebook(dot)com/ThePenetronGroup

SOURCE The Penetron Group

Share this article

SISU truck runs on hydrogen and electricity - the chargeable battery-fuel cell hybrid answers the challenges of emission-free heavy-duty transport

In late 2026, a pilot project exploring the possibilities of using hydrogen and electricity to power heavy-duty transport on long haul journeys will begin in Finland. The pilot aims to develop technology that contributes to the EU's objective of emission-free heavy road freight transport.

ESPOO, Finland, Oct. 21, 2026 /PRNewswire/ -- The pilot project, led by VTT Technical Research Centre of Finland, has introduced a high-tech hybrid truck combining electric mobility and hydrogen fuel cells in a unique way. The SISU Escalate truck, manufactured by Sisu Auto, runs primarily on electricity, and the hydrogen fuel cells serve as an alternative power source for quick charging on long haul assignments. The truck will start normal transport operation in late 2026, and its journey will be continuously monitored and measured through vehicle data and a digital twin.

"We will collect data on the technology, energy consumption, and overall functionality and reliability of different solutions. The vehicle will drive 540 kilometres per day, during which we will monitor how much electricity and hydrogen it is using," says Mikko Pihlatie, Research Professor at VTT.

The project involves several partners from Finland. The vehicle is manufactured by Sisu Auto, the battery system comes from IONCOR, Kempower supplies the MCS charging infrastructure, while Hevtec is responsible for the vehicle-side charging solution and the integration of the electric powertrain. The truck will be operated by Jylhä Logistics between Vuosaari harbour in southern Finland and the city of Jyväskylä in central Finland. The vehicle's first, full-electric version was tested in spring 2026 by logistics company Rauanheimo.

Monitoring reveals development areas

"By monitoring the truck for six months, we will gain data about the vehicle's performance, the ways different factors such as weather conditions impact consumption, and what limitations may occur in the operation of the vehicle. This information will help us develop the charging station network and optimise energy consumption," Pihlatie says.

The data will allow the pilot team to calculate the most economic ways of driving this kind of hybrid vehicle. Price data on hydrogen fuel and charging will enable the team to estimate how much energy should be loaded and where. The data is benchmarked against diesel-powered vehicles to assess cost benefits.

Finnish winter is a challenge

The truck will operate as an articulated vehicle and also take on regional distribution assignments in the Helsinki metropolitan area. It utilises Finland's first hydrogen fuel station built in Jyväskylä. There are charging stations at both ends of the long haul route, and a megawatt scale charging station will be built along it.

"A total of four trucks are piloted across Europe in this project, with different structures and power sources. SISU Escalate is the heaviest and longest of these. With its size and the difficult winter conditions in Finland, the operating environment of this truck is the most demanding of the four," says Pihlatie.

The vehicle will explore particularly how zero-emission powertrains and charging and fuel stations perform in vehicle configurations used in Finland and Sweden. The two countries use longer and heavier articulated vehicles weighing up to 76 tonnes, whereas in other parts of Europe, the total mass of articulated trucks tends to be around 40 tonnes. In this pilot, the gross vehicle combination weight is limited to 68 tonnes.

The truck includes a 650 kWh battery and, as a secondary power source, a fuel cell with a maximum power of 120 kW. Due to the hydrogen tanks and battery pack, the chassis is longer than usual for tractor units.

Truck full of high tech

The pilot is part of the EU-funded ESCALATE project, which aims to prove that a zero-emission heavy vehicle can operate reliably in real-world driving conditions.

"The SISU Escalate truck is not a product that will be launched in the market, but rather a means for testing the technology. With the learnings from the pilot, we can choose the best solutions for a product series developed for the market. The data will help us develop energy management systems and optimise driving with the battery to maximise the distance that can be driven with electricity. Hydrogen is, after all, the more expensive fuel," says Petri Kananen, Head of Development at Sisu Auto.

"Battery technology is a key element in the electrification of traffic. The pilot is carried out with a highly demanding setup: the modular battery platform must function in a 76-tonne articulated vehicle, in harsh winter conditions, and on a long-haul route," says Juuso Kelkka, Senior Manager of Technology Development at IONCOR. "With this truck, we can prove that a lithium-ion battery is a viable solution even in these conditions."

The vehicle will be on display at European Hydrogen Week in Brussels from 26 to 30 October.

For additional information:

Mikko Pihlatie, Research Professor, VTT

+358 400 430 395, [email protected] 

Petri Kananen Head of Development, Oy Sisu Auto Ab 

+358 50 468 1232, [email protected]

About ESCALATE

ESCALATE is a project funded by the EU's Horizon Europe programme that brings together 37 partners from 13 countries to develop and demonstrate next-generation zero-emission powertrain solutions for heavy-duty transport.

The project not only develops new technologies but also helps build the broader ecosystem needed for the transition to zero-emission freight transport, including standards, infrastructure, and the knowledge base on which Europe's future heavy-duty transport system can grow.

Heavy-duty road transport is one of Europe's most challenging climate issues. Trucks and other heavy-duty vehicles account for approximately one quarter of the EU's road transport CO₂ emissions. Electrification alone is not sufficient to address the challenge, as long-haul freight operations require extensive driving range, full payload capacity, and rapid refuelling. Current battery technologies alone cannot fully meet these requirements.

Project website: ESCALATE project website

Further information on VTT:

Kirsi Jaatinen

Communications Manager

+358 20 722 6757, [email protected] 

www.vtt.fi

This information was brought to you by Cision http://news.cision.com

Share this article

FREMONT, Calif. and BARCELONA, Spain, Oct. 21, 2026 /PRNewswire/ -- AglaiaSense and Leopard Imaging will exhibit together at Smart City Expo World Congress, November 3–5, 2026, at Fira Barcelona Gran Vía.

The two companies proposed AI-VIVA (Vision Intelligence for València and Arterials) and is selected as a finalist in the fifth urban challenge of Barcelona Innova Lab Mobility (BILM), on the application of artificial intelligence to traffic-light regulation. AI-VIVA combines AglaiaSense's edge-AI traffic solutions with Leopard Imaging's patented privacy architecture. At the show, the team will give a live demonstration of AglaiaSense's signature MS500 and GS500 cameras, with the AglaiaSense AI Box, powered by NVIDIA, which adds local processing to coordinate groups of neighboring intersections.

The cameras analyze images inside the device, using the Sony IMX500 and IMX501 intelligent vision sensors. They count and classify vehicles, buses, cyclists and pedestrians in real time. Raw video is discarded on the device within 400–800 milliseconds, and only anonymous metadata is transmitted. Cities can feed that data into signal-control software to adapt traffic lights to real demand.

"Cities want safer, smoother streets without turning every crossing into a surveillance point," said Leon Luo, CEO of AglaiaSense. "Being named a finalist in Barcelona tells us the approach resonates."

"Privacy has to be built into the camera, not added later," said Bill Pu, CEO of Leopard Imaging.

AglaiaSense's solutions are deployed across North America and Asia, and the company won first place in the Pedestrian Safety Challenge Hackathon, run by the Edge AI Foundation (formerly the tinyML Foundation) and the City of San José. In field tests, the systems achieved detection and counting accuracy above 95%. The City of Lakewood, Colorado, compared the GS500 with traditional IP cameras and LiDAR on real roads and found it more accurate, more energy-efficient, and less costly to deploy. At a high-risk crossing where pedestrians often crossed outside the crosswalk, the system alerted approaching drivers in real time.

Visit us at Pavilion 3, Level 0, Street D, Stand 71. To book a meeting, email [email protected].

About AglaiaSense

AglaiaSense, is an edge-AI company specializing in privacy-first, vision-based sensing for smart cities. Its GS500 and MS500 cameras run AI on the image sensor to count and classify road users in real time and send only anonymous metadata.

About Leopard Imaging

Leopard Imaging is a global leader in high-definition embedded cameras and AI-based imaging solutions in industries including automotive, aerospace, drones, IoT, and robotics.

Media contact:

Cathy Zhao

+1 (408) 263-0988

Share this article

MELBOURNE, Australia, Oct. 21, 2026 /PRNewswire/ -- The Board of Directors of CSL Limited (ASX:CSL; USOTC:CSLLY) today announces that it has appointed Deborah Waterhouse as Chief Executive Officer and Managing Director of CSL from 1 February 2027. The appointment was made following an extensive global search process conducted by CSL's Board of Directors. 

Ms Waterhouse is a proven commercial leader with more than 25 years' experience managing complex global specialty pharma companies across the U.S., the U.K., continental Europe and Australia.  

Since 2017 Ms Waterhouse has been the CEO of ViiV Healthcare, a joint venture majority owned by GSK with Shionogi as a shareholder. ViiV is a leading specialist in HIV and had sales of £7.7 billion during GSK's 2025 financial year[i]. Additionally, Ms Waterhouse serves as the President of GSK Global Health.

Ms Waterhouse has previously led GSK's U.S. vaccines business and its U.S. Primary Care business and has held several other senior executive positions, including GSK's General Manager for Australia and New Zealand between 2008 and 2012.

CSL Chair Dr Brian McNamee said, "In February this year we said CSL's next chief executive would need the ability to continue the momentum of our commercial performance, renew our pipeline and simplify our operations without losing the science and purpose that built this great company. Deborah has done all those things on multiple occasions. Deborah is an outstanding global leader with a proven ability to grow complex businesses."

"She has grown a focused biopharmaceutical business and renewed the franchise at ViiV by driving the development and commercialisation of the next generation of medicines to support patients. She knows the United States, she knows Australia and she knows how to build pipelines and manage partnerships. A world-class and purpose-driven executive, she is the right person to lead CSL in its next chapter of growth. The Board's decision to appoint Deborah was unanimous."

Ms Waterhouse said, "CSL is one of the great companies in our industry, and I saw what it means to Australia when I lived and worked in Melbourne. Its people save lives every day, from the staff who collect plasma at the donation centres to the scientists and operators who develop and manufacture the medicines and vaccines. The foundations are strong. My job is to continue the momentum and evolve the path into reliable growth for patients and shareholders."

Ms Waterhouse will retain her base in the U.K. She will spend significant time in Australia, the U.S. and in CSL's major markets and operational centres. Gordon Naylor will continue as Interim CEO and Managing Director until 1 February 2027. He will conduct an appropriate transition with Ms Waterhouse and will resume his role on the Board as a non-Executive Director. 

A biography for Ms Waterhouse is set out in Attachment 1.

The key components of Ms Waterhouse's employment contract, including her remuneration structure, effective from 1 February 2027 are set out in Attachment 2.

Authorised for lodgement by:

Fiona Mead

Company Secretary

Attachment 1: 

Career Summary for Ms Waterhouse

Attachment 2:

Key Employment Terms for Ms Waterhouse

[i] According to GSK's FY25 accounts

SOURCE CSL

Share this article

Respiratory Adverse Events of Weight-Loss Drugs: A Systematic Review and Meta-Analysis

This systematic review and meta-analysis pooled 123 studies evaluating respiratory adverse events of weight-loss drugs largely in general populations, with only one study specific to asthma patients. Liraglutide, semaglutide, tirzepatide, and naltrexone-bupropion showed no increased respiratory adverse events versus placebo, though nasopharyngitis and upper respiratory infections were common across drugs regardless of dose. Overall trial quality was rated low risk of bias, but evidence specific to asthmatic patients remains sparse, limiting firm conclusions for that subgroup. Urgent Care clinical implications: There was no evidence of increased respiratory harm associated with weight-loss drugs compared with placebo, suggesting a reassuring respiratory safety profile in the general population. However, evidence specifically focused on individuals with asthma remains limited. Full Access: Annals of the American Thoracic Society

Reliability of Physical Examination Findings in Youths Diagnosed With Pneumonia

A national PECARN-affiliated study led by Lurie Children’s Hospital of Chicago examined 252 children diagnosed with community-acquired pneumonia in emergency departments and found substantial disagreement between examiners on key auscultatory findings, including crackles, decreased breath sounds, and rhonchi. This mirrors earlier work (Florin et al., 2017) showing only fair-to-moderate interrater reliability for most CAP exam findings, with just wheezing, retractions, and respiratory rate reaching acceptable agreement. The authors conclude that physical exam alone is often insufficient to confidently diagnose pediatric pneumonia, reinforcing the value of adjunctive data. Urgent Care clinical implications: Current guidelines, including those from the Infectious Diseases Society of America, recommend that clinicians rely on physical examination findings to diagnose pediatric CAP in outpatient settings. However, the substantial variability in how these findings are recognized across clinicians suggests that use of auscultatory findings alone is not a reliable method for diagnosing CAP in youths. Full Access: JAMA

Whole-Blood Point-Of-Care Glial Fibrillary Acidic Protein and Ubiquitin C-Terminal Hydrolase L1 Biomarkers After Traumatic Brain Injury in the US: A Prospective Diagnostic Prediction of Intracranial Injury on Head CT

This prospective, multicenter regulatory trial showed biomarkers have a 96.5% sensitivity and 96.5% negative predictive value for detecting traumatic intracranial CT abnormalities, with a 3.5% false negative rate, and none of the false negatives required neurosurgical intervention. Specificity was lower at 40.3%, and all 14 lesions requiring potential neurosurgical intervention were correctly flagged as “elevated” by the test. The biomarkers are FDA-approved and now included in the ACS Trauma Quality Program 2024 Best Practices Guidelines for reducing unnecessary CT imaging. Urgent Care clinical implications: A negative point-of-care GFAP/UCH-L1 result (within 12–24h of injury) can support safely deferring head CT and considering outpatient management/referral for a stable mild-TBI patient (GCS 15), while an elevated result still warrants ED referral for imaging given the test’s low specificity (high false-positive rate). Full Access: The Lancet

FDA Authorizes Avulux Lens for Migraine-Related Light Sensitivity

The FDA granted De Novo marketing authorization to Avulux, an optical filtering lens for patients 12 and older with episodic migraine-associated light sensitivity — the first FDA-recognized device class in this category. Unlike traditional sunglasses, the lenses selectively filter light at 480nm (high blue) and 590nm (red/amber) wavelengths linked to triggering or worsening migraine attacks, while letting the rest of the visible spectrum through. It’s intended as a nonpharmacologic adjunct to standard migraine care, not a replacement, and is available over the counter. Urgent Care clinical implications: For patients presenting with acute migraine and prominent photophobia, this offers a low-risk, non-drug adjunct clinicians can mention alongside standard abortive therapy — but evidence for direct pain relief is modest and it shouldn’t delay or substitute for appropriate pharmacologic treatment, especially in moderate-to-severe attacks. Full Access: MRP

September 10, 2026

Last week, UCA Chief Executive Officer Steve Sellars attended and kicked off the inaugural Ohio Urgent Care Coalition Legislative Summit in Columbus.

The event brought together legislators, healthcare leaders and policy experts to discuss the issues impacting Urgent Care, and to explore opportunities for collaboration. This collaboration is a demonstration of what can happen when operators, brands and competitive interest come together around issues that matter to patients, employers, communities and the entire Urgent Care industry.

“Collaboration around issues like access, workforce, appropriate regulation and reimbursement makes all of us stronger.” – Steve Sellars, MBA

A full recap of the event will be shared in UCA’s Advocacy newsletter on Tuesday, September 15.

Great Urgent Care starts with exceptional people. That’s why UCA is excited to co-present the Staff Excellence Award with Experity at this year’s Limelight Awards. We want to recognize the individuals who go above and beyond to deliver outstanding patient care, elevate the patient experience and strengthen their teams every day.

This is your opportunity to shine a spotlight on the people who make Urgent Care exceptional.

Nominations are now open and must be submitted by October 15, 2026. Help recognize the unsung heroes of Urgent Care by nominating a deserving colleague today.

We’re excited to see the Southeast Regional Urgent Care Association (SERUCA) launch this valuable educational opportunity.

Join SERUCA’s free webinar, on Demystifying the Shoulder Exam on September 22. This free webinar will provide practical, real-world insights to help clinicians confidently assess and manage one of the most common musculoskeletal presentations in Urgent Care.

All are welcome to attend! Be sure to register and reserve your spot.

COVID-19 positivity rates are rising across the United States, reaching 4.6% as of August 22, according to CDC data, even as the FDA has approved four updated 2026-2027 COVID-19 vaccines targeting the XFG variant. The newly approved vaccines include formulations from Pfizer-BioNTech, Moderna and Sanofi/Novavax, with eligibility focused on adults age 65 and older and individuals with certain high-risk conditions.

While the overall burden of serious COVID-related illness remains relatively low, public health experts are watching closely after last year’s late-summer surge saw positivity rates climb to 12%. The seasonal increase has prompted questions about whether another back-to-school spike could emerge in the coming weeks.

Join Urgent Care professionals from September 23 – 25 at the California Urgent Care Association’s (CalUCA) Western Regional Urgent Care Conference in Santa Ana, CA. This event brings together owners, operators, clinicians, marketers and industry partners for three days of education, networking and collaboration focused on the future of Urgent Care.

Attendees will gain actionable insights on clinical best practices, operational excellence, technology innovations, regulatory developments and emerging leadership strategies. Whether you’re looking to enhance patient care, strengthen your organization or build valuable industry connections, the Western Regional Conference offers an unmatched opportunity to learn from experts, share ideas and grow alongside peers who are shaping the industry.

Registration is open for the 2026 North East Regional Urgent Care Association (NERUCA) Conference from October 4 – 6 in Montville, CT. This is where Urgent Care owners, operators, clinicians and vendors will convene for an enriching experience focused on Urgent Care leadership and hands-on skills development.

This dynamic event aims to address pressing industry challenges while offering essential continuing medical education (CME) courses for providers.

Attendees will have ample networking opportunities to connect, share insights and explore collaborative solutions in the ever-evolving landscape of Urgent Care.

AFC Urgent Care Wichita has earned Accreditation, Urgent Care Certification, Occupational Health Certification, Antibiotic Stewardship Commendation and Specialty Training Commendation recognition for its center in Kansas.

This initial achievement reflects the organization’s commitment to maintaining the highest standards of quality, safety and consistency in patient care. These distinctions highlight AFC Urgent Care Wichita’s dedication to exceptional patient experiences, clinical excellence and operational best practices.

AllMed Urgent Care, PC, serving three centers across New York, has successfully renewed its Accreditation and Urgent Care Certification.

This outstanding achievement reflects an ongoing commitment to excellence and highlights the dedication, collaboration and operational discipline required to uphold these high standards. This reinforces their position as a leader in delivering trusted, high-quality care while ensuring safety, consistency and accountability across all three locations.

The College of Urgent Care Medicine is proud to welcome Michael Stephens, MSN, AAS-EMTP, APRN, FNP-C, FCUCM, in our latest class of Fellows.

Michael brings a diverse healthcare background spanning emergency medical services, hospice care, home health and Urgent Care. Currently serving as a Nurse Practitioner and Lead APP for Pelican Urgent Care/Ochsner Health, he provides comprehensive care to patients of all ages while helping lead clinician recruitment, onboarding, quality improvement initiatives, staff development and clinical operations across multiple clinic locations.

Known for his strong leadership and dedication to clinical excellence, his career reflects a steadfast commitment to improving patient outcomes, supporting colleagues and advancing the role of advanced practice clinicians within Urgent Care.

We congratulate Michael Stephens, MSN, AAS-EMTP, APRN, FNP-C, FCUCM on this well-deserved achievement and look forward to his continued contributions to the specialty of Urgent Care.

The College of Urgent Care Medicine is proud to welcome Huai Lee Phen, MD, FCUCM, in our latest class of Fellows.

Dr. Phen is a board-certified Family Medicine physician, USAF Flight Surgeon, educator and Urgent Care leader whose career spans clinical care, academic medicine and military service. As a Staff Physician with Northwell Health GoHealth Urgent Care and Core Faculty member for the GoHealth Urgent Care Fellowship Program, he combines clinical excellence with a passion for mentoring the next generation of healthcare professionals.

In addition to his contributions to Urgent Care and academic medicine, Dr. Phen serves as a Flight Surgeon Captain in the United States Air Force Reserve, providing aeromedical readiness evaluations and operational medical support for military aircrew. His unique combination of clinical, academic and military experience exemplifies the leadership, service and excellence recognized through Fellowship.

We congratulate Huai Lee Phen, MD, FCUCM on this well-deserved achievement and look forward to his continued contributions to the advancement of Urgent Care medicine.

The College of Urgent Care Medicine is proud to welcome Scott A. Fiorini, DMSc, PA-C, CAQ-EM, RT(R)(ARRT), FCUCM, in our latest class of Fellows.

A board-certified Physician Associate with more than a decade of experience in emergency medicine, Urgent Care, occupational medicine and diagnostic imaging, Scott has built a distinguished career centered on clinical excellence, provider development and quality improvement. His unique background combines advanced clinical training with expertise in medical imaging, occupational health and emergency medicine, allowing him to deliver comprehensive, evidence-based patient care across a variety of healthcare settings.

Throughout his career, Scott has served in numerous leadership and educational roles, including Advanced Practice Provider Director, APP and Physician Scheduling Coordinator, and Primary Clinical Preceptor. A passionate mentor and educator, he has helped shape the development of future healthcare professionals while promoting best practices in clinical care.

We congratulate Scott A. Fiorini, DMSc, PA-C, CAQ-EM, RT(R)(ARRT), FCUCM on this well-deserved achievement and look forward to his continued contributions to the future of Urgent Care medicine.

Interested in becoming a Fellow? Learn more below.

Urgent Updates are curated highlights of guidelines, reviewed by (and some directly coming from) Urgent Care clinicians. These highlights represent the actual intent of these articles and how they relate to the practice of Urgent Care medicine.

Tuesday, September 15 | 11 am – 12 pm CT

More healthcare organizations are exploring voice AI, but figuring out where to start can be tricky. This session is a chance to understand how the technology works, see where it’s already being used, and learn what to consider before making an investment.

Join Teresa Asma, COO at Solv, and Kapeesh Saraf, CPO at Solv, for a 45-minute session on what voice AI looks like in practice, with insights from more than 1 million patient calls, real call examples, and a look at where the technology is headed next.

Learning Objectives:

Wednesday, September 30 | 2 pm – 3 pm CT

Who is this session for:

Urgent Care owners and decision makers who want strategies for DME and bracing profitability – either by cost avoidance or by revenue generation; in order to improve financial performance without increasing administrative load.

Conversation highlights:

Featured speakers:

Urgent Insights are timely conversations impacting the business of Urgent Care.

This session is sponsored by Enovis as part of the UCA Urgent Insights series. Urgent Insights is a sponsored educational discussion facilitated by the Urgent Care Association (UCA). Sponsorship and participation do not constitute endorsement by UCA of any company, product, service, recommendation, position, or viewpoint expressed during the session.